These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30625326)

  • 21. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
    Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
    Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus.
    Li Y; Chen Z; Wu L; Dai L; Qi J; Chai Y; Li S; Wang Q; Tong Z; Ma S; Duan X; Ren S; Song R; Liang M; Liu W; Yan J; Gao GF
    Innovation (Camb); 2022 Nov; 3(6):100323. PubMed ID: 36199277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA interference inhibits yellow fever virus replication in vitro and in vivo.
    Pacca CC; Severino AA; Mondini A; Rahal P; D'avila SG; Cordeiro JA; Nogueira MC; Bronzoni RV; Nogueira ML
    Virus Genes; 2009 Apr; 38(2):224-31. PubMed ID: 19169857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zika Virus Envelope Protein and Antibody Complexes.
    Dai L; Wang Q; Song H; Gao GF
    Subcell Biochem; 2018; 88():147-168. PubMed ID: 29900496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination reshapes the virus-specific T cell repertoire in unexposed adults.
    Pan YG; Aiamkitsumrit B; Bartolo L; Wang Y; Lavery C; Marc A; Holec PV; Rappazzo CG; Eilola T; Gimotty PA; Hensley SE; Antia R; Zarnitsyna VI; Birnbaum ME; Su LF
    Immunity; 2021 Jun; 54(6):1245-1256.e5. PubMed ID: 34004140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody.
    Wang L; Wang R; Wang L; Ben H; Yu L; Gao F; Shi X; Yin C; Zhang F; Xiang Y; Zhang L
    Cell Rep; 2019 Mar; 26(12):3360-3368.e5. PubMed ID: 30893607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Fusion Loops of the Initial Prefusion Conformation of Herpes Simplex Virus 1 Fusion Protein Point Toward the Membrane.
    Fontana J; Atanasiu D; Saw WT; Gallagher JR; Cox RG; Whitbeck JC; Brown LM; Eisenberg RJ; Cohen GH
    mBio; 2017 Aug; 8(4):. PubMed ID: 28830949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.
    Kim AS; Austin SK; Gardner CL; Zuiani A; Reed DS; Trobaugh DW; Sun C; Basore K; Williamson LE; Crowe JE; Slifka MK; Fremont DH; Klimstra WB; Diamond MS
    Nat Microbiol; 2019 Jan; 4(1):187-197. PubMed ID: 30455470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence.
    Gould EA; Buckley A
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1605-8. PubMed ID: 2543793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.
    Thibodeaux BA; Garbino NC; Liss NM; Piper J; Schlesinger JJ; Blair CD; Roehrig JT
    Antiviral Res; 2012 Apr; 94(1):1-8. PubMed ID: 22366350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice.
    Desprès P; Dietrich J; Girard M; Bouloy M
    J Gen Virol; 1991 Nov; 72 ( Pt 11)():2811-6. PubMed ID: 1834798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
    Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
    mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Sensitive Yellow Fever Virus Entry Reporter Identifies Valosin-Containing Protein (VCP/p97) as an Essential Host Factor for Flavivirus Uncoating.
    Ramanathan HN; Zhang S; Douam F; Mar KB; Chang J; Yang PL; Schoggins JW; Ploss A; Lindenbach BD
    mBio; 2020 Apr; 11(2):. PubMed ID: 32291299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies.
    Gould EA; Buckley A; Cammack N; Barrett AD; Clegg JC; Ishak R; Varma MG
    J Gen Virol; 1985 Jul; 66 ( Pt 7)():1369-82. PubMed ID: 2410549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target.
    Albarnaz JD; De Oliveira LC; Torres AA; Palhares RM; Casteluber MC; Rodrigues CM; Cardozo PL; De Souza AM; Pacca CC; Ferreira PC; Kroon EG; Nogueira ML; Bonjardim CA
    Antiviral Res; 2014 Nov; 111():82-92. PubMed ID: 25241249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.
    Zandi K; Amblard F; Amichai S; Bassit L; Tao S; Jiang Y; Zhou L; Ollinger Russell O; Mengshetti S; Schinazi RF
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.